VTGN Key Statistics, Chart & Performance
The current stock price of VTGN is 0.6619 USD. In the past month the price decreased by -81.61%. In the past year, price decreased by -80.18%.
VTGN Latest News, Press Relases and Analysis
VTGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.18 | 403.83B | ||
| AMGN | AMGEN INC | 14.97 | 176.25B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.12 | 115.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.71 | 52.53B | ||
| INSM | INSMED INC | N/A | 37.12B | ||
| NTRA | NATERA INC | N/A | 31.62B | ||
| BIIB | BIOGEN INC | 10.51 | 25.82B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.46 | 20.98B | ||
| INCY | INCYTE CORP | 15.38 | 19.39B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About VTGN
Company Profile
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. The company is headquartered in South San Francisco, California and currently employs 59 full-time employees. The company went IPO on 2010-10-18. The firm is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
Company Info
VISTAGEN THERAPEUTICS INC
343 Allerton Avenue
South San Francisco CALIFORNIA 94080 US
CEO: Shawn K. Singh
Employees: 59
Phone: 16505773600
VISTAGEN THERAPEUTICS INC / VTGN FAQ
What does VTGN do?
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. The company is headquartered in South San Francisco, California and currently employs 59 full-time employees. The company went IPO on 2010-10-18. The firm is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
What is the current price of VTGN stock?
The current stock price of VTGN is 0.6619 USD. The price decreased by -2.39% in the last trading session.
What is the dividend status of VISTAGEN THERAPEUTICS INC?
VTGN does not pay a dividend.
How is the ChartMill rating for VISTAGEN THERAPEUTICS INC?
VTGN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about VISTAGEN THERAPEUTICS INC (VTGN) stock?
11 analysts have analysed VTGN and the average price target is 7.4 USD. This implies a price increase of 1017.24% is expected in the next year compared to the current price of 0.6619.
Can you provide the PE ratio for VTGN stock?
VISTAGEN THERAPEUTICS INC (VTGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.9).
What is the expected growth for VTGN stock?
The Revenue of VISTAGEN THERAPEUTICS INC (VTGN) is expected to grow by 3.47% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
VTGN Technical Analysis
VTGN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VTGN. The financial health of VTGN is average, but there are quite some concerns on its profitability.
VTGN Financial Highlights
Over the last trailing twelve months VTGN reported a non-GAAP Earnings per Share(EPS) of -1.9. The EPS decreased by -53.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -63.53% | ||
| ROE | -77.51% | ||
| Debt/Equity | 0.01 |
VTGN Forecast & Estimates
11 analysts have analysed VTGN and the average price target is 7.4 USD. This implies a price increase of 1017.24% is expected in the next year compared to the current price of 0.6619.
For the next year, analysts expect an EPS growth of -11.54% and a revenue growth 3.47% for VTGN